CN114099558A - 一种刺山柑果提取物的制备方法及其应用 - Google Patents
一种刺山柑果提取物的制备方法及其应用 Download PDFInfo
- Publication number
- CN114099558A CN114099558A CN202111473158.7A CN202111473158A CN114099558A CN 114099558 A CN114099558 A CN 114099558A CN 202111473158 A CN202111473158 A CN 202111473158A CN 114099558 A CN114099558 A CN 114099558A
- Authority
- CN
- China
- Prior art keywords
- caper
- supernatant
- water
- ethanol
- leaching
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000722721 Capparis Species 0.000 title claims abstract description 44
- 235000017336 Capparis spinosa Nutrition 0.000 title claims abstract description 42
- 239000000284 extract Substances 0.000 title claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000006228 supernatant Substances 0.000 claims abstract description 29
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 19
- 210000001072 colon Anatomy 0.000 claims abstract description 19
- 238000002386 leaching Methods 0.000 claims abstract description 16
- 239000002244 precipitate Substances 0.000 claims abstract description 15
- 238000001914 filtration Methods 0.000 claims abstract description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 238000007605 air drying Methods 0.000 claims abstract description 5
- 238000005238 degreasing Methods 0.000 claims abstract description 5
- 238000012869 ethanol precipitation Methods 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000000967 suction filtration Methods 0.000 claims abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000003544 deproteinization Effects 0.000 abstract 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 14
- 229960004963 mesalazine Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 208000035861 hematochezia Diseases 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 244000140995 Capparis spinosa Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- -1 qRT-PCR kit Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种刺山柑果提取物的制备方法及其应用,按如下步骤:去脂:刺山柑粉末,添加乙醇进行浸提;热水浸提:真空抽滤弃上清,滤渣加水,水浴后,超声辅助,再次真空抽滤,滤渣反复浸提多次,收集每次上清液;脱蛋白:将全部上清液置于真空旋转蒸发仪水浴浓缩10倍后脱蛋白,按浓缩液∶Sevage试剂=3∶1比例混合,磁力搅拌,抽滤保留上清,反复脱蛋白数次;乙醇沉淀:添加无水乙醇至脱蛋白上清中使醇浓度达到80%,4℃过夜,抽滤弃上清,保留沉淀,无水乙醇洗沉淀一次,再用丙酮洗一次,自然晾干,得刺山柑水提物;用于治疗溃疡性结肠炎,具有抗炎、改善结肠组织病理形态的作用。
Description
技术领域
本发明涉及藤蔓类植物加工及应用技术领域,具体涉及一种刺山柑果提取物的制备方法及其应用。
背景技术
溃疡性结肠炎(UC)是一种慢性非特异性炎症性肠病,主要表现为腹痛、腹泻、里急后重及黏液脓血便等,病程迁延,多反复发作,严重时可发展为结肠癌,严重影响患者的生命质量。我国现有的流行病学资料统计数据显示,UC患病率、发病率均呈上升趋势,已成为我国的常见病和多发病。目前UC尚无特异的治疗方法,西医主要运用抗生素、糖皮质激素、5-氨基水杨酸(5-ASA)以及免疫抑制剂治疗,虽能够短期内缓解症状,但迁延难愈,尤其是对于顽固性UC治疗效果不理想。由于目前针对UC的治疗欠佳,大部分治疗方法及药物只能缓解病情,患者需要长期靠药物维持病情稳定,然而疾病仍易复发,因此,寻找新的研究方向以便更有效治疗UC迫在眉睫。
刺山柑(Capparis spinosa Linn.)属于山柑科山柑属植物,又名马槟榔、野西瓜,为藤本半灌木,根较长,呈辐射分布,叶呈圆形或椭圆形,极端耐旱,生于荒漠或半荒漠地带,在我国大多分布于新疆、甘肃、西藏等地区。刺山柑中含有丰富的黄酮、糖苷硫苷、生物碱、脂质及挥发性成分等。研究表明刺山柑具有多种药理活性,包括抑菌,抗炎止痛,抗氧化,降糖降脂,降血压,改善记忆,保肝及抗肿瘤等,刺山柑是一种常用的药用植物,在临床上主要用于银屑病、肩周炎、硬皮病、痛风及类风湿性关节炎等疾病的治疗。目前刺山柑多糖在治疗UC方面还未见报道。
因此,本领域技术人员提供了一种刺山柑果提取物的制备方法及其应用,以解决上述背景技术中提出的问题。
发明内容
为解决上述技术问题,本发明提供一种刺山柑果提取物的制备方法,刺山柑果实粉碎后过60目筛备用,刺山柑粗多糖的提取及定量按如下步骤:
(1)、去脂:刺山柑粉末,添加乙醇进行浸提;
(2)、热水浸提:真空抽滤弃上清,滤渣加水,水浴后,超声辅助,离心取上清,滤渣反复浸提多次,收集每次上清液;
(3)、脱蛋白:将全部上清液置于真空旋转蒸发仪水浴浓缩10倍后脱蛋白,按浓缩液∶Sevage试剂=3∶1比例混合,磁力搅拌,抽滤保留上清,反复脱蛋白数次;
(4)、乙醇沉淀:添加无水乙醇至脱蛋白上清中使醇浓度达到80%,4℃过夜,抽滤弃上清,保留沉淀,无水乙醇洗沉淀一次,再用丙酮洗一次,自然晾干,得刺山柑水提物;
(5)、得到0.22mm的过滤器除菌后密封保存。
优选的:所述步骤(1)中加入乙醇的体积占混合体积的95%,体积为1L,浸提时间为2h。
优选的:所述步骤(2)中加入1L温度为80℃的水,80℃搅拌3h。
优选的:所述步骤(2)中超声辅助时间为30min(50℃,300W)。
优选的:所述步骤(2)中离心为3000rpm,15min。
优选的:所述步骤(3)中真空旋转蒸发仪内水温为55℃。
优选的:所述步骤(4)自然晾干时间为3-4h。
本发明提供了一种刺山柑果提取物,该提取物主治溃疡性结肠炎,具有抗炎、改善结肠组织病理形态的作用。
本发明的技术效果和优点:
本发明用于治疗溃疡性结肠炎,能够有效减轻溃疡性结肠炎的炎症反应,改善肠道组织病理形态。
附图说明
图1是本发明药理学作用实验中各组小鼠体重变化图;
图2是本发明药理学作用实验中各组小鼠疾病活动指数分析图;
图3是本发明药理学作用实验中各组小鼠结肠形态对比图;
图4是本发明药理学作用实验中各组小鼠结肠长度分析图;
图5是本发明药理学作用实验中小鼠结肠组织形态变化;
图6是本发明药理学作用实验中各组小鼠小肠组织形态变化图;
图7是本发明药理学作用实验中炎性细胞因子的表达图;
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细的说明。本发明的实施例是为了示例和描述起见而给出的,而并不是无遗漏的或者将本发明限于所公开的形式。很多修改和变化对于本领域的普通技术人员而言是显而易见的。选择和描述实施例是为了更好说明本发明的原理和实际应用,并且使本领域的普通技术人员能够理解本发明从而设计适于特定用途的带有各种修改的各种实施例。
请参阅图1~7,在本实施例中提供一种刺山柑果提取物的制备方法,刺山柑果实粉碎后过60目筛备用,刺山柑粗多糖的提取及定量按如下步骤:
(1)、去脂:刺山柑粉末,添加乙醇进行浸提;
(2)、热水浸提:真空抽滤弃上清,滤渣加水,水浴后,超声辅助,离心取上清,滤渣反复浸提多次,收集每次上清液;
(3)、脱蛋白:将全部上清液置于真空旋转蒸发仪水浴浓缩10倍后脱蛋白,按浓缩液∶Sevage试剂=3∶1比例混合,磁力搅拌,抽滤保留上清,反复脱蛋白数次;
(4)、乙醇沉淀:添加无水乙醇至脱蛋白上清中使醇浓度达到80%,4℃过夜,抽滤弃上清,保留沉淀,无水乙醇洗沉淀一次,再用丙酮洗一次,自然晾干,得刺山柑水提物;
(5)、得到0.22mm的过滤器除菌后密封保存。
实施例1
在本实施例中提供一种刺山柑果提取物的制备方法,刺山柑果实粉碎后过60目筛备用,刺山柑粗多糖的提取及定量按如下步骤:
(1)、去脂:刺山柑粉末100g,添加95%乙醇1L浸提2h;
(2)、热水浸提:真空抽滤弃上清,滤渣加水1L,80℃搅拌3h后,超声辅助30min(50℃,300W),再次真空抽滤,滤渣反复浸提4次,收集每次上清液;
(3)、脱蛋白:将全部上清液置于真空旋转蒸发仪55℃水浴浓缩10倍后脱蛋白,按浓缩液∶Sevage试剂=3∶1比例混合,磁力搅拌30min,抽滤保留上清,反复脱蛋白数次;
(4)、乙醇沉淀:添加无水乙醇至脱蛋白上清中使醇浓度达到80%,4℃过夜,抽滤弃上清,保留沉淀,无水乙醇洗沉淀一次,再用丙酮洗一次,自然晾干3h得刺山柑水提物;
(5)、得到0.22mm的过滤器除菌后密封保存。
药理学作用的实验:
1试验材料
实验动物:6-8周龄雄性昆明小鼠。
植物:采自新疆维吾尔自治区吐鲁番市风干的刺山柑果实,按上述方法制备刺山柑水提物。
试验材料:葡聚糖硫酸钠(DSS),美沙拉嗪(5-ASA),qRT-PCR试剂盒,糖原PAS染料试剂,Trizol试剂,甲苯胺蓝染料,氯仿,正丁醇,苯酚,硫酸,二甲苯,冰醋酸,无水乙醇。
2试验动物分组及处理
将小鼠随机分为5组(n=7),分别为对照(Untreated)组、葡聚糖硫酸钠(DSS)处理组、低浓度刺山柑粗水提物(CSWE(L))治疗组、高浓度刺山柑粗水提物(CSWE(H))治疗组和5-ASA阳性对照组。对照组给予蒸馏水,其余各组给予3%(wt/vol)DSS(MW 50000)连续7天诱导UC小鼠模型。DSS给药后,CSWE(L)组和CSWE(H)组分别灌胃200、400mg/kg/d的CSWE,5-ASA组灌胃220mg/kg/d的美沙拉嗪,连续7d。试验期间每隔一天记录体重和粪便出血度,评估疾病活动指数(DAI)以评判严重程度(见表1)。
表2-1疾病活动指数评分
3小鼠体重及结肠组织形态变化观察
试验期间小鼠隔天称重同时观察小鼠体重变化、粪便稀疏度及是否便血。第15天断颈处死小鼠,用无菌解剖刀,在无菌状态下取出整个肠道,测量结肠的长度。处死小鼠后,取结肠组织,过夜固定于4%多聚甲醛溶液中,然后经脱水、石蜡包埋,连续切片,随后对切片进行苏木精和伊红(Hematoxylin-eosinstaining,HE)染色,封片后在显微镜下观察拍照。并对组织病变程度进行评分(表2)。
表2组织学疾病评分
4炎性细胞因子的测定
(1)使用TRIzol试剂从结肠组织中提取RNA。
(2)用研钵在液氮中将组织磨碎,倒入EP管中。
(3)每管加入1mL预先冷却的TRIzol试剂,反复吹打至混匀后在冰盒中静置5min直至溶液澄清。
(4)将EP管在12000rpm离心5min后,收取上清液,加入200μ预冷氯仿,混匀后静置15min,12000rpm离心15min。
(5)收取无色上清液,加入500μL预冷的异丙醇混匀后静置5min,12000rpm离心10min,弃上清。
(6)将1mL预冷的DEPC水加入EP管中,12000rpm离心5min后,弃上清,此操作重复两次后,静置于冰上干燥8-10min。
(7)待提取的RNA干燥后,加入50μL RNase-Free H2O溶解RNA反复吹打,充分混匀后放置冰上静置20min,测定RNA浓度和纯度后,放入-80℃中备用。
(8)使用反转录试剂盒根据说明合成的cDNA,PCR在以下条件中进行:95℃持续10分钟,95℃持续15秒,52℃持续30秒(根据目标基因退后温度),72℃持续45秒,40个循环。使用2-ΔΔCt方法计算基因的相对表达量。引物详细序列见表3-2。
表3 qRT-PCR引物序列
5试验结果
5.1体征变化
体重减轻,食欲不振,腹泻和便血是DSS诱导的结肠炎的典型特征。在DSS建模期间,于第3天开始出现食欲不振,粪便稀疏,第5天时体重明显下降,观察到不同程度的腹泻及明显的便血,表明建模成功。建模后CSWE给药期间,小鼠体征逐渐恢复,给药第五天,小鼠体重及粪便恢复正常状态。统计分析结果表明,与对照组相比,葡聚糖硫酸钠模型组(DSS组),低浓度治疗组(200mg/ml CSWE组)体重显著降低(P<0.05);高浓度治疗组(400mg/mlCSWE组)与阳性对照(5-ASA组)无显著差异(图1)。疾病活动指数结果显示,DSS建模后DAI评分明显升高,而CSWE(L),CSWE(H)组和5-ASA组DAI评分明显降低(如图2所示)。
5.2小鼠结肠形态学观察
各组小鼠结肠形态对比如图3,DSS建模组小鼠结肠充血肿胀,且结肠长度明显缩短,CSWE给药治疗后能够明显改善结肠充血肿胀及长度缩短特征,统计分析结果表明与对照组相比,DSS建模组结肠长度显著降低(P<0.05),其余治疗组呈现明显缓解小鼠结肠缩短的趋势(如图4所示)。
5.3 CSWE对DSS诱导的UC小鼠结肠及小肠组织学形态的影响
小鼠结肠组织的组织化学染色显微照片显示,DSS诱导的溃疡性结肠炎小鼠肠上皮细胞损失,杯状细胞浸润及隐窝损失严重(如图5a所示)。CSWE治疗后使隐窝恢复,肠上皮细胞及杯状细胞损害减轻,与阳性对照5-ASA治疗结果相一致。组织学疾病评分(如图5b所示)与DSS组相比,其余治疗组评分结果均显著低于DSS组(P<0.001)。
小鼠小肠组织的组织化学染色显微照片显示,DSS诱导的溃疡性结肠炎小鼠小肠绒毛严重受损,CSWE及5-ASA治疗后显著改善了肠绒毛受损情况(如图6a所示),且小肠绒毛量化结果(如图6b所示)同样表明CSWE及5-ASA治疗后小肠绒毛长度显著高于DSS组(P<0.05)。
5.4 CSWE对DSS诱导的UC小鼠炎性细胞因子的影响
与对照组相比,DSS组干扰素-1β(IL-1β)的表达显著增加(P<0.01),肿瘤细胞坏死因子α(TNF-α),白细胞介素-6(IL-6)及干扰素-γ(IFN-γ)明显升高,但无显著差异(图7)。与DSS组相比,CSWE治疗后显著降低了IL-1β的表达水平(P<0.01),且CSWE(H)处理组IL-6及IFN-γ的表达显著下降(P<0.05),CSWE(L)无显著差异,但呈下降趋势,表明CSWE治疗具有剂量依赖性。阳性对照5-ASA组结果表明促炎性细胞因子均呈现显著下降(P<0.05),CSWE治疗结果与阳性对照5-ASA治疗结果趋于一致(如图7所示)。
主治溃疡性结肠炎,具有抗炎、调控肠道菌群的效果。
临床表现为:腹痛、腹泻、里急后重及黏液脓血便等,治疗不及时则会导致贫血、消瘦、低蛋白血症和水电解质紊乱。
显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域及相关领域的普通技术人员在没有作出创造性劳动的前提下所获得的所有其他实施例,都应属于本发明保护的范围。本发明中未具体描述和解释说明的结构、装置以及操作方法,如无特别说明和限定,均按照本领域的常规手段进行实施。
Claims (7)
1.一种刺山柑果提取物的制备方法,包括刺山柑果实粉碎后过60目筛备用,其特征在于,刺山柑粗多糖的提取及定量按如下步骤:
(1)、去脂:刺山柑粉末,添加乙醇进行浸提;
(2)、热水浸提:真空抽滤弃上清,滤渣加水,水浴后,超声辅助,离心取上清,滤渣反复浸提多次,收集每次上清液;
(3)、脱蛋白:将全部上清液置于真空旋转蒸发仪水浴浓缩10倍后脱蛋白,按浓缩液∶Sevage试剂=3∶1比例混合,磁力搅拌,抽滤保留上清,反复脱蛋白数次;
(4)、乙醇沉淀:添加无水乙醇至脱蛋白上清中使醇浓度达到80%,4℃过夜,抽滤弃上清,保留沉淀,无水乙醇洗沉淀一次,再用丙酮洗一次,自然晾干,得刺山柑水提物;
(5)、得到0.22mm的过滤器除菌后密封保存。
2.根据权利要求1所述的一种刺山柑果提取物的制备方法,其特征在于,所述步骤(2)中加入1L温度为80℃的水,80℃搅拌3h。
3.根据权利要求1所述的一种刺山柑果提取物的制备方法,其特征在于,所述步骤(2)中超声辅助时间为30min(50℃,300W)。
4.根据权利要求1所述的一种刺山柑果提取物的制备方法,其特征在于,所述步骤(2)中离心为3000rpm,15min 。
5.根据权利要求1所述的一种刺山柑果提取物的制备方法,其特征在于,所述步骤(3)中真空旋转蒸发仪内水温为55℃。
6.根据权利要求1所述的一种刺山柑果提取物的制备方法,其特征在于,所述步骤(4)自然晾干时间为3-4h。
7.一种由权利要求1-6任一项所述刺山柑果提取物的应用,其特征在于,该提取物主治溃疡性结肠炎,具有抗炎、改善结肠组织病理形态的作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111473158.7A CN114099558A (zh) | 2021-12-06 | 2021-12-06 | 一种刺山柑果提取物的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111473158.7A CN114099558A (zh) | 2021-12-06 | 2021-12-06 | 一种刺山柑果提取物的制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114099558A true CN114099558A (zh) | 2022-03-01 |
Family
ID=80366607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111473158.7A Pending CN114099558A (zh) | 2021-12-06 | 2021-12-06 | 一种刺山柑果提取物的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114099558A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114949017A (zh) * | 2022-06-27 | 2022-08-30 | 新疆前进荣耀投资有限公司 | 一种刺山柑醇提物、制备方法及其在制备抗氧化产品和/或降血脂产品中的应用 |
CN116889574A (zh) * | 2023-07-13 | 2023-10-17 | 深圳市中医院 | 白扁豆多糖在制备预防和/或治疗溃疡性结肠炎的产品中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101406497A (zh) * | 2008-11-26 | 2009-04-15 | 上海中医药大学 | 刺山柑提取物及其制备方法与应用 |
CN102091104A (zh) * | 2009-12-15 | 2011-06-15 | 上海医药工业研究院 | 从刺山柑中获得精制提取物的方法及该提取物的应用 |
CN109381497A (zh) * | 2017-08-08 | 2019-02-26 | 上海医药工业研究院 | 刺山柑提取物、其制备方法及应用 |
-
2021
- 2021-12-06 CN CN202111473158.7A patent/CN114099558A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101406497A (zh) * | 2008-11-26 | 2009-04-15 | 上海中医药大学 | 刺山柑提取物及其制备方法与应用 |
CN102091104A (zh) * | 2009-12-15 | 2011-06-15 | 上海医药工业研究院 | 从刺山柑中获得精制提取物的方法及该提取物的应用 |
CN109381497A (zh) * | 2017-08-08 | 2019-02-26 | 上海医药工业研究院 | 刺山柑提取物、其制备方法及应用 |
Non-Patent Citations (3)
Title |
---|
张瑜等: "刺山柑多糖提取及其抗炎镇痛作用研究", 《石河子大学学报(自然科学版)》 * |
朱晓薇等: "维药刺山柑水提物的降血糖作用研究", 《农垦医学》 * |
李明学: "槌果藤的药理研究", 《新疆中医药》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114949017A (zh) * | 2022-06-27 | 2022-08-30 | 新疆前进荣耀投资有限公司 | 一种刺山柑醇提物、制备方法及其在制备抗氧化产品和/或降血脂产品中的应用 |
CN116889574A (zh) * | 2023-07-13 | 2023-10-17 | 深圳市中医院 | 白扁豆多糖在制备预防和/或治疗溃疡性结肠炎的产品中的应用 |
CN116889574B (zh) * | 2023-07-13 | 2024-06-04 | 深圳市中医院 | 白扁豆多糖在制备预防和/或治疗溃疡性结肠炎的药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114099558A (zh) | 一种刺山柑果提取物的制备方法及其应用 | |
CN112076205B (zh) | 黄精多糖在制备治疗溃疡性结肠炎的药物中的应用 | |
Simayi et al. | Isolation, structural characterization, biological activity, and application of Glycyrrhiza polysaccharides: Systematic review | |
He et al. | Research progress on extraction, purification, structure and biological activity of Dendrobium officinale polysaccharides | |
Chiu et al. | The pharmacological and pathological studies on several hepatic protective crude drugs from Taiwan (I) | |
CN112641921B (zh) | 一种治疗溃疡性结肠炎的蜚蠊多肽有效部位及其制备方法和用途 | |
CN109010776B (zh) | 一种外用止痛剂及其制备方法 | |
CN109280090B (zh) | 一种具有温肾壮阳活性的九香虫类蝽科昆虫多糖提取方法和应用 | |
CN113712999B (zh) | 一种壮药血党干膏粉在制备抗炎镇痛药物中的应用 | |
CN114304640B (zh) | 一种保护胃黏膜的多糖组合物及其制备方法与应用 | |
CN112370440B (zh) | 一种百里香-迷迭香抗腹泻制剂及其制备方法及其应用 | |
CN105796625A (zh) | 含红曲红花的药物组合物及其制剂 | |
CN104225472A (zh) | 一种治疗口腔粘膜病变的中药制剂及制备方法和用途 | |
CN103229895A (zh) | 一种大黄提取物及其应用 | |
Yu et al. | A study on the antitumour effect of total flavonoids from Pteris multifida Poir in H22 tumour-bearing mice | |
CN113527531A (zh) | 一种太子参多糖及其制备方法 | |
CN109718268B (zh) | 红豆树种子提取物的制备方法及其在抗炎药物中的应用 | |
CN109288978B (zh) | 能有效改善急性炎症损伤的中药复方制剂及其制备方法 | |
CN115671131B (zh) | 白簕多糖在制备治疗高尿酸疾病药物中的应用 | |
CN110812396A (zh) | 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法和应用 | |
WO2019114159A1 (zh) | 一种油茶粕多肽、多糖及其制备方法、应用和油茶粕脱毒方法 | |
CN114425058B (zh) | 一种治疗鼻炎的中药组合物及其制备方法、药物和制剂 | |
CN114712351B (zh) | 钩藤碱在制备治疗炎症性肠炎药物中的应用 | |
CN115006475B (zh) | 组合物及其在用于防治高尿酸血症和保护肝肾的药物中的应用 | |
CN117683150B (zh) | 一种沙棘果皮多糖及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220301 |